Skip to main content
Brainify.AI logo

Brainify.AI

New York, NYFounded 2021

  • EEG and neural monitoring
  • Seed

Brainify.AI builds brain data infrastructure for longevity centers and biopharma. Its offering combines a 10-minute brain-wave assessment, a collection of more than 500,000 brain scans, and AI-based biomarkers to support central nervous system development.

Raised
$4M
Aug 2025
Seed
Investor
1
Founded
2021
Employees
11–50

reccy insights

Recent highlights

On Jul 14, 2026, Brainify.AI launched Brainify.AI Longevity at The Longevity Suite’s Riyadh clinic, pairing a short, non-invasive brain assessment with a personalized wellness report. The launch partnership is intended to support expansion to additional locations in Saudi Arabia and potentially the wider region. The product extends the company’s brain-measurement work into premium longevity and wellness settings, alongside its biopharma and clinical research focus. In October 2025, Brainify.AI also announced a European distribution partnership for its BREEG technology with Reguard Health GmbH. Its latest disclosed financing was a $2.3 million Seed round announced on Aug 31, 2025; total funding is $4.05 million across six rounds. The company describes its platform as serving drug-development programs in PTSD, generalized anxiety disorder and Parkinson’s disease, with partners including HB Bio, Negev Labs and Newleos Therapeutics. Earlier milestones include a 2023 precision-psychiatry partnership with Clerkenwell Health and a January 2024 appearance by CEO and co-founder Mariam Khayretdinova at the World Economic Forum on AI and psychiatry. The available profile does not identify awards or executive changes.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes Brainify.AI distinct

  1. 01Combines brain-wave assessment, large-scale brain scan data and AI-based biomarkers in one offering.
  2. 02Offers a brain-wave assessment designed to take about 10 minutes.
  3. 03Supports both longevity centers and biopharma programs working on central nervous system development.
  4. 04Connects neuroscience, AI, data science and healthcare capabilities.
  5. 05Scientific advisors are described as including leaders from academic medicine and the pharmaceutical industry.

Technology & products6

  • Foundational EEG AI Model

    An AI model trained on extensive EEG data to analyze brain signals for diagnostics, treatment prediction and research in neurology and psychiatry.

  • BREEG Portable EEG System

    A lightweight, wireless EEG headset with integrated AI analytics for rapid brain monitoring and clinical reporting.

  • EEG-Based Companion Diagnostics (CDx) Platform

    A platform using EEG biomarkers to stratify patients in clinical trials and inform treatment decisions, compatible with standard EEG devices.

Recent updates2

  • Jul 14, 2026Product launch

    Brainify.AI launched its Brainify.AI Longevity brain wellness assessment platform at The Longevity Suite clinic in Riyadh, offering fast, non-invasive EEG-based cognitive wellness reports.

    prnewswire.com
  • Jul 14, 2026Partnership

    Brainify.AI and The Longevity Suite partnered to deploy the Brainify.AI Longevity brain wellness assessment at The Longevity Suite’s Riyadh clinic, with plans to expand to additional locations in Saudi Arabia and potentially the wider region.

    prnewswire.com

Funding

$4M disclosed
  • SeedAug 2025
    $2.3M
  • Pre-SeedOct 2023
    $150KLed by Merck Digital Sciences Studio
  • Pre-SeedJan 2023
    $1M
1 investor

Similar companies

About Brainify.AI

Products
Foundational EEG AI Model, BREEG Portable EEG System, EEG-Based Companion Diagnostics (CDx) Platform, Dataset Hub, Research-as-a-Service for Biopharma, Brainify.AI Longevity
Leadership
Mariam Khayretdinova, CEO & FounderIvan Mishanin, COO and co-founder
Focus areas
Neurotechnology, digital health, medical devices, AI/ML, diagnostics, brain data, biomarkers, clinical research
Headquarters
New York, NY
Founded
2021
Employees
11–50